6CM
TCRX icon

683 Capital Management’s TScan Therapeutics TCRX Stock Holding History

683 Capital Management’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-43,198
Closed -$252K – 251
2023
Q4 		$252K Buy
+43,198
New +$198K 0.02% 152

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

683 Capital Management's TCRX Position: Q1 2024 in Review

683 Capital Management sold out of TScan Therapeutics (TCRX) in Q1 2024, closing a stake of 43,198 shares — an estimated $252K sold.

683 Capital Management first reported a position in TCRX in Q4 2023 and held it in 1 quarter. The position peaked at $252K in Q4 2023. 66 funds tracked by Wall St. Rank hold TCRX as of Q1 2024.

  • 683 Capital Management reported no remaining TScan Therapeutics position as of Q1 2024 after selling out during the quarter.
  • 683 Capital Management sold 43,198 TScan Therapeutics shares in Q1 2024, an estimated $252K.
  • 683 Capital Management first reported a position in TScan Therapeutics in Q4 2023 and held it in 1 quarter.
  • 683 Capital Management's TScan Therapeutics position peaked at $252K in Q4 2023.
  • 66 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2024.

Based on 683 Capital Management's 13F filing for Q1 2024, filed 15 May 2024.